Lantheus Holdings, Inc. (NASDAQ:LNTH) Holdings Boosted by Reinhart Partners LLC.

Reinhart Partners LLC. grew its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 9.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,366,873 shares of the medical equipment provider's stock after purchasing an additional 123,282 shares during the period. Lantheus makes up approximately 4.7% of Reinhart Partners LLC.'s investment portfolio, making the stock its 2nd biggest position. Reinhart Partners LLC. owned 1.97% of Lantheus worth $122,280,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Wilmington Savings Fund Society FSB purchased a new stake in Lantheus during the 3rd quarter valued at $25,000. Signaturefd LLC raised its stake in shares of Lantheus by 40.5% in the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider's stock valued at $35,000 after acquiring an additional 92 shares during the period. UMB Bank n.a. lifted its holdings in shares of Lantheus by 42.1% in the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider's stock worth $47,000 after acquiring an additional 126 shares during the last quarter. Kathleen S. Wright Associates Inc. purchased a new position in shares of Lantheus during the 3rd quarter worth about $51,000. Finally, GAMMA Investing LLC raised its position in Lantheus by 45.5% in the 3rd quarter. GAMMA Investing LLC now owns 467 shares of the medical equipment provider's stock worth $51,000 after purchasing an additional 146 shares during the period. 99.06% of the stock is owned by institutional investors.

Lantheus Stock Down 1.3 %

Shares of LNTH stock traded down $1.23 during mid-day trading on Monday, hitting $94.65. 1,059,744 shares of the stock were exchanged, compared to its average volume of 867,235. Lantheus Holdings, Inc. has a 52-week low of $50.20 and a 52-week high of $126.89. The company has a market cap of $6.58 billion, a PE ratio of 15.75 and a beta of 0.46. The firm has a fifty day moving average of $90.39 and a 200 day moving average of $99.69.

Analyst Upgrades and Downgrades

Several research analysts recently commented on LNTH shares. JMP Securities reduced their price target on shares of Lantheus from $125.00 to $112.00 and set a "market outperform" rating on the stock in a research note on Thursday, November 7th. Truist Financial reaffirmed a "buy" rating and set a $120.00 price target (down previously from $135.00) on shares of Lantheus in a research note on Friday, November 8th. StockNews.com downgraded Lantheus from a "buy" rating to a "hold" rating in a report on Thursday, November 21st. Finally, The Goldman Sachs Group started coverage on Lantheus in a report on Wednesday, December 18th. They issued a "buy" rating and a $143.00 target price for the company. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $131.86.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.